Myozyme (Alglucosidase Alfa)

Alglucosidase alfa is a recombinant version of the missing human enzyme acid alpha‑glucosidase. After intravenous infusion, it is taken up by cells via the mannose‑6‑phosphate receptor and delivered to lysosomes, where it breaks down accumulated glycogen into glucose, reducing cellular storage and improving organ performance.

The dosage of Myozyme is individualized by the prescribing physician based on factors such as the patient’s body weight, disease severity, age, and clinical response. The prescriber decides the infusion rate and total amount required for each treatment cycle.

Safety data for Myozyme in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To order Myozyme, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

The primary alternative to Myozyme is avalglucosidase alfa (Lumizyme), another recombinant acid alpha‑glucosidase. Both provide enzyme replacement, but they differ in molecular structure, dosing schedules, and regulatory approvals. Clinical choice depends on factors such as patient response, immunogenicity risk, and regional availability.

Myozyme must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Myozyme is given as an intravenous infusion. The infusion is typically administered over several hours under medical supervision, with vital signs monitored before, during, and after the infusion to detect any adverse reactions.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, respiratory distress or bronchospasm, cardiac arrhythmias, and significant liver enzyme elevations or thrombocytopenia. Immediate medical attention is required if any of these events occur.

Myozyme is contraindicated in individuals with known hypersensitivity to alglucosidase alfa or any of its excipients. Patients with uncontrolled severe cardiac disease or those who have experienced a serious infusion‑related reaction should also avoid treatment until evaluated by a specialist.